Pexidartinib is an oral TKI with selective inhibition of CSF1R, which has been approved by the FDA for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TSGCT) that is associated with severe morbidity or functional limitations and not responsive to improvement with surgery. This evidence concerns the gene CSF1R and tenosynovial giant cell tumor, diffuse type.